



Product Information Sheet for HRP-9481

Lopinavir

Catalog No. HRP-9481

This reagent is the property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:

Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID)

Manufacturer:

Ambeed, Inc.

Product Description:

Lopinavir (brand name: Kaletra) is an antiretroviral protease inhibitor used in combination with ritonavir in the therapy and prevention of human immunodeficiency virus (HIV) infection.¹ It prevents cleavage of the *gag-pol* polyprotein, resulting in the production of immature, non-infectious viral particles.

Material Provided:

Each vial contains approximately 20 mg of lopinavir.

Packaging/Storage:

HRP-9481 was packaged in glass serum vials and is provided on dry ice. HRP-9481 should be stored at 2°C to 8°C, protected from light immediately upon arrival. The vial should be centrifuged prior to opening.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, NIAID, NIH: Lopinavir, HRP-9481, contributed by DAIDS/NIAID."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at www.hivreagentprogram.org.

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Park, S., et al. "HIV-1 Protease Inhibitors Slow HPV16-Driven Cell Proliferation through Targeted Depletion of Viral E6 and E7 Oncoproteins." *Cancers* 13 (2021): 949. doi: 10.3390/cancers13050949. PubMed: 33668328.

ATCC® is a trademark of the American Type Culture Collection.



NIH HIV Reagent Program

www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org

Tel: 888-487-0727 | Fax: 703-365-2898

© 2022 American Type Culture Collection (ATCC)

All rights reserved.

HRP-9481_07APR2022

Page 1 of 1